BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Other Non-current Assets
Long-term assets not reported separately.
BioAge Labs, Inc.NASDAQ: BIOA
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets rises 692.9% from a year ago
Other non-current assets stood at $1.9M at the end of Q1 FY2026, up 692.9% from a year earlier and down 55.4% from the prior quarter. Over 3 fiscal years it compounded at +453.9% a year.
Context
- Other non-current assets amounted to 0.5% of total assets at the end of Q1 FY2026, up 0.4 pp from a year earlier.
- Other non-current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +692.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 4.25M USD
- Year-over-year change
- +1670.0%
- 3-year CAGR
- +453.9%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.25M | +1670.0% |
| FY2024 | 2024-12-31 | 240K | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 25K | — |
Other Non-current Assets vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so other non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +692.9% is the highest of 9, against a peer median of -40.3%.
- Other non-current assets amounts to 0.5% of total assets for BIOA, versus a peer median of 1.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$80.57M CAD | -50.0% | -32.8% | 7.2% | |
| Dec 2025 | $8.7M USD | — | — | 3.7% | |
| Mar 2026 | $5.27M USD | +122.6% | +109.0% | 3.6% | |
| Mar 2026 | CA$3.63M CAD | -52.8% | -38.8% | 0.6% | |
| Mar 2026 | $3.53M USD | -89.6% | +23.5% | 0.9% | |
| Mar 2026 | $3.05M USD | -30.6% | +28.0% | 1.1% | |
BIOABioAge Labs, Inc. | Mar 2026 | $1.9M USD | +692.9% | +453.9% | 0.5% |
| Mar 2026 | $1.2M USD | -9.4% | -17.1% | 1.2% | |
| Mar 2026 | $672K USD | -98.7% | — | 0.6% | |
| Mar 2026 | $306K USD | -4.7% | -62.5% | 0.2% | |
| Peer median (excluding BIOA) | — | -40.3% | -17.1% | 1.1% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.